Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extreme Hypofractionation with SBRT in Localized Prostate Cancer.
Gómez-Aparicio MA, Valero J, Caballero B, García R, Hernando-Requejo O, Montero Á, Gómez-Iturriaga A, Zilli T, Ost P, López-Campos F, Couñago F. Gómez-Aparicio MA, et al. Curr Oncol. 2021 Aug 3;28(4):2933-2949. doi: 10.3390/curroncol28040257. Curr Oncol. 2021. PMID: 34436023 Free PMC article. Review.
Importance of 68Ga-PSMA PET/CT in hospital practice. View of the radiation oncologist.
Couñago F, Artigas C, Sancho G, Gómez-Iturriaga A, Gómez-Caamaño A, Maldonado A, Caballero B, López-Campos F, Recio M, Del Cerro E, Henríquez I. Couñago F, et al. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018 Sep-Oct;37(5):302-314. doi: 10.1016/j.remn.2018.07.005. Epub 2018 Aug 20. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018. PMID: 30139594 Review. English, Spanish.
Oligometastatic prostate cancer: The game is afoot.
Lancia A, Zilli T, Achard V, Dirix P, Everaerts W, Gomez-Iturriaga A, Ingrosso G, Liefhooghe N, Miralbell R, Siva S, Van der Eecken K, Ost P. Lancia A, et al. Cancer Treat Rev. 2019 Feb;73:84-90. doi: 10.1016/j.ctrv.2019.01.005. Epub 2019 Jan 17. Cancer Treat Rev. 2019. PMID: 30684842 Review.
Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study.
Büchser D, Casquero F, Espinosa JM, Perez F, Minguez P, Martinez-Indart L, Suarez F, Gonzalez A, Cacicedo J, San Miguel I, Maleta A, Gomez-Caamaño A, Bilbao P, Gomez-Iturriaga A. Büchser D, et al. Radiother Oncol. 2019 Jun;135:13-18. doi: 10.1016/j.radonc.2019.02.018. Epub 2019 Mar 5. Radiother Oncol. 2019. PMID: 31015158
Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT.
Gomez-Iturriaga A, Casquero Ocio F, Ost P, Fernandez I, Rodeño E, Llarena R, Garcia-Olaverri J, Ortiz de Zarate R, Cacicedo J, Ahtamon A, Bilbao P. Gomez-Iturriaga A, et al. Eur J Cancer Care (Engl). 2019 Sep;28(5):e13093. doi: 10.1111/ecc.13093. Epub 2019 May 21. Eur J Cancer Care (Engl). 2019. PMID: 31115124
Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
De Bleser E, Jereczek-Fossa BA, Pasquier D, Zilli T, Van As N, Siva S, Fodor A, Dirix P, Gomez-Iturriaga A, Trippa F, Detti B, Ingrosso G, Triggiani L, Bruni A, Alongi F, Reynders D, De Meerleer G, Surgo A, Loukili K, Miralbell R, Silva P, Chander S, Di Muzio NG, Maranzano E, Francolini G, Lancia A, Tree A, Deantoni CL, Ponti E, Marvaso G, Goetghebeur E, Ost P. De Bleser E, et al. Eur Urol. 2019 Dec;76(6):732-739. doi: 10.1016/j.eururo.2019.07.009. Epub 2019 Jul 20. Eur Urol. 2019. PMID: 31331782
67 results